KRAS and colorectal carcinoma: A retrospective study found that regular aspirin use was associated with reduced risk of BRAF wild-type CRC but not with BRAF-mutated CRC.107 Another study showed that postdiagnostic NSAID use, including aspirin, improved overall survival only in patients with KRAS wild-type tumors (HR = 0.60, 95% CI [0.46–0.80]) compared to KRAS-mutated tumors (HR = 1.24, 95% CI [0.78–1.96]).108 In this study, BRAF mutation status was not predictive of postdiagnostic aspirin efficacy.